Evidence map›Paper›PMID 25614278›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

Myocardin regulates vascular smooth muscle cell inflammatory activation and disease.

Matthew Ackers-Johnson, Amarnath Talasila, Andrew P Sage, Xiaochun Long, Ilze Bot, Nicholas W Morrell, Martin R Bennett, Joseph M Miano, Sanjay Sinha

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Spatial expression of myocardin protein in normal and disease states.American journal of physiology. Cell physiology · 2026
    Article
  4. Review
  5. Genetic silencing of KChannels (Austin, Tex.) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Matthew Ackers-JohnsonFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Amarnath TalasilaFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Andrew P SageFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Xiaochun LongFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Ilze BotFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Nicholas W MorrellFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Martin R BennettFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Joseph M MianoFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.).
Sanjay SinhaFrom the Department of Medicine, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom (M.A.-J., A.T., A.P.S., N.W.M., M.R.B., S.S.); Department of Medicine, AAB Cardiovascular Research Institute, West Henrietta, NY (X.L., J.M.M.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (I.B.). ss661@cam.ac.uk.
Leiden University · NL

Funding

Regulation of Vascular Smooth Muscle Cell Phenotype by a Novel Isoform of Glucose-6-Phosphate DehydrogenaseR01HL132574 · NHLBI · NEW YORK MEDICAL COLLEGE · PI GUPTE, SACHIN A, MIANO, JOSEPH M · 2017 to 2020
$2.5M
Regulation and Function of Myocardin in Vascular PathobiologyR01HL117907 · NHLBI · UNIVERSITY OF ROCHESTER · PI MIANO, JOSEPH M · 2013 to 2016
$1.5M
British Heart Foundation FS/13/29/30024British Heart Foundation PG/10/007/28184British Heart Foundation RG/08/009/25841British Heart Foundation RG/13/14/30314British Heart Foundation RG/13/4/30107Medical Research Council G0800784Medical Research Council G1000847NHLBI NIH HHS HL-117907NHLBI NIH HHS R01 HL117907NHLBI NIH HHS R01 HL132574Wellcome TrustWellcome Trust 086799/Z/08/Z
6 · The paper itself

Abstract

objectiveAtherosclerosis, the cause of 50% of deaths in westernized societies, is widely regarded as a chronic vascular inflammatory disease. Vascular smooth muscle cell (VSMC) inflammatory activation in response to local proinflammatory stimuli contributes to disease progression and is a pervasive feature in developing atherosclerotic plaques. Therefore, it is of considerable therapeutic importance to identify mechanisms that regulate the VSMC inflammatory response. APPROACH AND

resultsWe report that myocardin, a powerful myogenic transcriptional coactivator, negatively regulates VSMC inflammatory activation and vascular disease. Myocardin levels are reduced during atherosclerosis, in association with phenotypic switching of smooth muscle cells. Myocardin deficiency accelerates atherogenesis in hypercholesterolemic apolipoprotein E(-/-) mice. Conversely, increased myocardin expression potently abrogates the induction of an array of inflammatory cytokines, chemokines, and adhesion molecules in VSMCs. Expression of myocardin in VSMCs reduces lipid uptake, macrophage interaction, chemotaxis, and macrophage-endothelial tethering in vitro, and attenuates monocyte accumulation within developing lesions in vivo. These results demonstrate that endogenous levels of myocardin are a critical regulator of vessel inflammation.

conclusionsWe propose myocardin as a guardian of the contractile, noninflammatory VSMC phenotype, with loss of myocardin representing a critical permissive step in the process of phenotypic transition and inflammatory activation, at the onset of vascular disease.

Indexed as

AnimalsApolipoproteins EAtherosclerosisCarotid Artery InjuriesCell AdhesionCell Adhesion MoleculesCells, CulturedChemokinesChemotaxisCytokinesDisease Models, AnimalGenotypeHumansHuman Umbilical Vein Endothelial CellsInflammationLipid MetabolismApolipoproteins ECell Adhesion MoleculesChemokinesCytokinesMyocardinNuclear ProteinsTrans-Activatorsatherosclerosisinflammationmyocardinsmooth muscle

Identifiers

PMID25614278
PMCPMC4390125
OpenAlexW2044406870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.